Abstract
Increased breakdown of myocardial phospholipids to fatty acids and lysophosphoglycerides is an early feature of myocardial ischemic injury and many investigators believe that enhanced phospholipase action is an important factor in the process. Several recent reports indicate that inhibitors of phospholipase A, such as mepacrine, chloroquine and chlorpromazine, can prevent heart phosphoglyceride breakdown in vivo. We isolated the phospholipases A from rat heart cytosol and sarcoplasmic reticulum and examined the effects of various cardioprotective substances on their activity. Most of the cardioprotective agents studied inhibited the heart phospholipases in vitro, providing further evidence that phospholipid degradation in ischemic myocardial injury may be modulated by pharmacologic agents.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jennings RB, Reimer KA: Lethal myocardial ischemic injury. Am J Pathol 102: 241–255, 1981
Katz AM, Messineo FC: Lipid-membrane interactions and the pathogenesis of ischemic damage in the myocardium. Circ Res 48: 1–16, 1981
Taylor IM, Shaikh NA, Downar E: Ultrastructural changes of ischemic injury due to coronary artery occlusion in the porcine heart. J Mol Cell Cardiol 16: 79–94, 1984
Sobel BE, Corr PB, Robison AK, Goldstein RA, Witkowski FX, Klein MS: Accumulation of lysophosphoglycerides with arrhythmogenic properties in ischemic myocardium. J Clin Invest 62: 546–553, 1978
Shaikh NA, Downar E: Time course of changes in porcine myocardial phospholipid levels during ischemia. A reassessment of the lysolipid hypothesis. Circ Res 49: 316–325, 1981
Corr PB, Snyder DW, Lee BI, Gross RW, Keim CR, Sobel BE: Pathophysiological concentrations of lysophosphatides and the slow response. Am J Physiol 243: H187-Hl95, 1982
Mann RYK, Slater TL, Pelletier MP, Choy PC: Alterations of phospholipids in ischemic canine myocardium during acute arrhythmia. Lipids 18: 677–681, 1983
Chien KR, Han A, Sen A, Buja IM, Willerson IT: Accumulation of unesterified arachidonic acid in ischemic canine myocardium, Cite Res 54: 313–322, 1984
Prinzen FW, van der Vusse GJ, Arts T, Roemen THM, Coumans WA, Reneman RS: Accumulation of nonesterified fatty acids in ischemic canine myocardium, Am J Physiol 247: H264–272, 1984
Vasdev SC, Biro GP, Narbaitz R, Kako KJ: Membrane changes induced by early myocardial ischemia in the dog, Can J Biochem 58: 1112–1119, 1980
Chien KR, Pfau RG, Farber JL: Ischemic myocardial cell injury: prevention by chlorpromazine of an accelarated phospholipid degradation and associated membrane dysfunction, Am J Pathol 97: 505–530, 1979
Yanagishita T, Konno N, Geshi E, Katagiri T: Alterations in phospholipids in acute ischemic myocardium, Japan Cite J 51: 41–50, 1987
Steenbergen C, Jennings RB: Relationship between lysophospholipid accumulation and plasma membrane injury during total in vitro ischemia in dog heart. J Mol Cell Cardiol 16: 605–621, 1984
Okumura K, Ogawa K, Satake T: Pretreatment with chlorpromazine prevents phospholipid degradation and creatine kinase depletion in isoproterenol-induced myocardial damage in rats, J Cardiovasc Pharmacol 5: 983–988, 1983.
Das DK, Engelman RM, Ronson JA, Breyer RH, Otani H, Lemeshow S: Role of membrane phospholipids in myocardial injury induced by ischemia and reperfusion, Am J Physiol 251: H71–79, 1986
Chiariello M, Ambrosio G, Cappelli-Bigazzi M, Nevola E, Perrone-Fillardi P, Marone G, Condorelli M: Inhibition of ischemia-induces phospholipase activation by quinacrine protects jeopardized myocardium in rats with coronary artery occlusion, J Pharmacol Exp Therap 241: 560–568, 1987
Kayawake S, Narbaitz, Kako KJ: Effects of chloroquine and nifedipine on the phospholipid content and enzyme activity in the subcellular fraction of ischemic rat liver, Basic Res Cardiol 77: 140–157, 1982
Kajiyama K, Pauly DF, Hughes H, Yoon SB, Entman M, McMillin-Wood JB: Protection by verapamil of mitochondrial glutathione equilibrium and phospholipid changes during reperfusion of ischemic canine myocardium, Circ Res 61: 301–310, 1987
Trotz M, Jellison EJ, Hostetler KY: Propranolol inhibition of the neutral phospholipases A of rat heart mitochondria, sarcoplasmic reticulum and cytosol, Biochem Pharmacol 36:4251–4256, 1987
Trotz M, Hein L, Hostetler KY: Solubilization and partial characterization of phospholipase A from rat heart sarcoplasmic reticulum, Biochim Biophys Acta 962: 248–257, 1988
Nalbone G, Hostetler KY, Leonardi J, Trotz M, Lafont H: Partial characterization of rat heart cytosolic phospholipase A and demonstration of essential sulfhydryl groups, Biochim Biophys Acta, 877: 88–95, 1986
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurements with the Folin phenol reagent, J Biol Chem 193:265–275, 1951
Van den Bosch H, Aarsman AJ: A review on methods of phospholipase determination, Agents Actions 9: 382–389, 1979
Hostetler KY, Yazaki PJ, van den Bosch H: Purification of lysosomal phospholipase A: evidence for multiple isoenzymes, J Biol Chem 257: 13367–13373, 1982
Hostetler KY, Giordano JR, Jellison EJ: In vitro inhibition of lysosomal phospholipase A of rat lung by amiodarone and desethylamiodarone, Biochim Biophys Acta 959: 316–321, 1988
Hostetler KY: Phospholipid fatty liver: an acquired disease of impaired phospholipid catabolism. In: JAF op den Kamp, B Roelofsen and KWA Wirtz (eds), Lipids an 324, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hostetler, K.Y., Jellison, E.J. Role of phospholipases in myocardial ischemia: effect of cardioprotective agents on the phospholipases A of heart cytosol and sarcoplasmic reticulum in vitro. Mol Cell Biochem 88, 77–82 (1989). https://doi.org/10.1007/BF00223427
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00223427